STOCKS TELEGRAPH

Author: Shimrez Hyder

  • Alset Ehome Intl. Inc. (AEI) Stock Plummets Following Public Offering News Despite Promising Partnership with Puradigm

    Alset Ehome Intl. Inc. (AEI) stock prices were down 11.43% as of the market closing on July 27th, 2021, bringing the price per share down to USD$3.41 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 34.60%, bringing it down to USD$2.23.

    Partnership with Puradigm

    July 27th 2021 saw the company announced having entered into a Sales of Goods Agreement with Puradigm LLC, which will facilitate the securing of innovative and patented air and surface purification solutions. These solutions will be incorporated into AEI stock’s eco-friendly single-family home communities. The company’s products are set to be integrated into its pipeline of Alset EHomes to dramatically minimize the risk of pathogenic infections while ensuring improved standards of health and wellness.

    Purifier Technology

    Puradigm’s patented purification technology produces Non-Thermal Plasma (NTP) particles, which have been demonstrated to be effective against a myriad of pathogens, including Covid-19. With its aim of facilitating health and wellness around the world, the company manufactures proactive air and surface purification solutions. These safety and scalability of the solutions has been proven, with the solutions providing 24/7 protection for indoor environments of any kind.

    Scope of AEI Stock’s Collaboration

    The company’s innovative and patented purifier technologies are leaders in their marketspace, having been proven to be effective against a large collection of pathogens, including, but not limited to, Covid-19 and its variants, H1N1, E.coli, MRSA, Listeria, C. difficile, and staph. The company’s technology carves its own path from existing disinfection technologies that are currently available, such as chemical cleaning, UV light, and vaporized hydrogen peroxide. The patented purifier technology produces NTP particles in vast quantities, which serves to actively purify both air and surfaces in a safe and timely manner.

    Purifier Functionality

    The highly energized plasma molecules kill bacteria and viruses by piercing their cell walls, akin to the popping of a balloon by pricking it with something sharp. Perhaps most significant, AEI stock’s purifiers can be activated safely within people’s vicinity, with no downtime periods. There are also no harmful residues, room clearance protocols, manpower requirements or any other known adverse side effects.

    Future Outlook for AEI Stock

    Armed with the recent collaboration with Puradigm, AEI stock is poised to capitalize on the expanded scope of the commercialization of its products. The company is keen to spearhead a growing market to maximize market penetration, with investors hoping this translates into significant and sustained increases in shareholder value.

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment

    Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

    FleX SN-PEEK Shipments

    July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

    About FleX SN-PEEK

    The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

    Advantages of FleX SN-PEEK

    The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

    SINT Stock Healthcare Scope

    The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

    Future Outlook for SINT

    Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

  • The Cheesecake Factory, Inc. (CAKE) Stock Exhibiting Minor Volatility Following Disclosure of Promising Q2 2021 Financial Report

    The Cheesecake Factory, Inc. (CAKE) stock prices were up to USD$0.90% as of the market close on July 27th, 2021, bringing the price per share up to USD$55.01 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.65%, bringing it down to USD$51.90.

    Revenue Reports

    Total revenues for the second quarter of fiscal 2021, ended June 29th, 2021, were reported at USD$769 million. This is a significant improvement over the USD$295.9 million in the prior-year quarter. Net income attributable to common stockholders came in at USD$17.1 million, while diluted net income per common share was USD$0.37 for Q2 2021.

    Additional Financials

    The quarter saw CAKE stock report USD$11.4 million in non-cash acquisition-related contingent consideration and amortization expense. The amortization expense was primarily associated with the amendment to the Fox Restaurant Concepts acquisition agreement, including the extension of the earn-out period through to 2026. Adjusted net income for the quarter came out to USD$43.9 million, representing an adjusted net income per share of USD$0.80.

    CAKE Stock Recovering from Pandemic

    CAKE stock’s restaurants in almost their entirety are operating with no indoor dining restrictions. Comparable sales for the company during the Fiscal 2021 third quarter-to-date were up 61% as compared to the prior year period and 10% as compared to the 2019 period. This increase was largely supported by a 27% off-premise sales mix. On the basis of roughly USD$230,000 in average weekly sales quarter-to-date, this represents nearly USD$12 million on average, per unit on an annualized basis. Off-premise average weekly sales were almost twice the numbers reported for the fiscal 2019 period.

    Solid Liquidity Position

    CAKE stock reported a solid liquidity position of USD$401.9 million as of June 29th, 2021, which included a cash balance of USD$161.8 million and USD$240.1 million available through the company’s revolving credit facility. Total principal amount of debt outstanding was USD$475 million as of the end of the quarter, which included USD$345 million in 0.375% convertible senior notes that were issued during Q2 2021 and will be due in 2026. The company also reported USD$130 million drawn on its revolving credit facility, following from the USD$150 million repayment announced during the quarter.

    Future Outlook for CAKE

    Armed with the financial success of the second quarter of 2021, CAKE stock is poised to capitalize on the opportunities it finds presented to it for Q3 2021. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Relmada Therapeutics Inc. (RLMD) Stock Continues Downward Trend Despite Promising Top-line Data from REL-1017 Study

    Relmada Therapeutics Inc. (RLMD) stock prices were down 3.26% some time after market trading commenced on July 27th, 2021, bringing the price per share down to USD$24.30 early on in the trading day.

    Positive REL-1017 Topline Data

    July 27th 2021 announced the top-line results of the human abuse potential study with REL-1017, the company’s lead candidate. The novel NMDA receptor channel blocker is in Phase 3 development for the treatment of the major depressive disorder (MDD). Top-line results indicated all three doses of REL-1017 tested in recreational opioid users demonstrated a highly statistically significant difference from the control group. The 25mg, 75mg, and 150mg therapeutic, supratherapeutic, and maximum tolerated doses were compared to the active control drug, oxycodone 40 mg.

    RLMD Stock’s Study Endpoints

    The primary endpoint of the study was a measure of ‘likability’ with the subjects rating the maximum effect for Drug Liking “at the moment” using a 1=100 bipolar rating scale. The visual analog scale (VAS) has 100 as the highest likeability, 50 as the neutral, and the 0 as the highest dislike. The data clearly shows a very meaningful difference between the REL-1017 treatment and oxycodone at all three tested doses.

    Safety of REL-1017

    The results consolidate previous findings about the lack of opioid effects of REL-1017. RLMD stock is keen to continue the clinical development of REL-1017 as a novel, safe, and rapidly effective treatment for MDD. The findings have been consistent with RLMD stock’s development programs and confirms what has already been established by an extensive body of literature that indicates the lack of abuse potential of REL-1017. The results strongly support the ongoing REL-1017 late-stage development program.

    Consolidated Scope for RLMD Stock

    The results are in line with HAP results that have been seen for other drugs that affect the CNS and have been scheduled at Classes IV or V, or remain unscheduled, during the assessment and review period. RLMD stock is keen to address the large unmet need for patients suffering from depression in the absence of safe and rapidly effective treatments.

    Future Outlook for RLMD

    Armed with the promising topline results from its study of REL-1017, RLMD is poised to capitalize on the enormous marketspace it finds needing to be addressed. Current and potential investors are hopeful that management will be able to leverage the resources at their diposal to facilitate significant and sustained increases in shareholder value.

  • Travena, Inc. (TRVN) Stock Exhibits Minor Volatility Following First Patient Enrolment in ACTIV-4 Host Tissue Trial

    Travena, Inc. (TRVN) Stock Exhibits Minor Volatility Following First Patient Enrolment in ACTIV-4 Host Tissue Trial

    Travena, Inc. (TRVN) stock prices were down 3.24% shortly after market trading commenced on July 27th, 2021, bringing the price per share down to USD$1.3464.

    First Patient Enrolment

    July 26th, 2021 saw TRVN stock announce the enrollment of its first patient in the ACTIV-4 Host Tissue (Accelerating Covid-19 Therapeutic Interventions and Vaccines) trial. With the end of Covid-19 requiring a multi-pronged solution, TRVN stock is excited to be developing TRV027 as a pioneering active treatment arm available for patient randomization.

    ACTIV-4 Host Tissue Trial

    The ACTIV-4 Host Tissue trial serves to evaluate four investigational agents that fight dysregulation of the renin-angiotensin-aldosterone system (RAAS) and immune system irregularities caused by Covid-19 infections. The treatment is a novel AT1 receptor selective agonist that targets the AT1 receptor to bind to within the RAAS, thereby obstructing the damaging pathway that results in acute lung damage and abnormal blood clotting. TRVN stock’s treatment activates the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.

    TRVN Stock’s Efforts Against Pandemic

    More than 1600 patients will be enrolled across 50 sites spanning the United States for the TRVN stock’s trial. TRV027 is part of the initial trial launch, with additional study arms being added to the trial over time. The study will serve to evaluate the impact of each intervention on recovery, supplemental oxygen use, need for mechanical ventilation, organ failure, and mortality. As the global Covid-19 pandemic continues to devastate the globe, the development of interventions remains a top priority, aiming to combat the vascular, fibrotic, and inflammatory damage done by the virus.

    About the Trial

    The ACTIV-4 Host Tissue is a multi-site, randomized, placebo-controlled clinical trial with multiple treatment arms. Each arm is expected to enroll roughly 300-400 Covid-19 patients that are 18 years of age or older. The four trial arms will test investigational agents that target the RAAS or immune system through distinct mechanisms of action. The trial is designed for TRVN stock to determine whether modulation of these systems is a viable solution to preventing progression to critical illness in hospitalized Covid-19 patients.

    Future Outlook for TRVN Stock

    Armed with the initiation of patient testing in its ACTIV-4 Host Tissue trial, TRVN stock is poised to capitalize on the opportunities afforded to it. The company is keen to leverage the resources at its disposal to usher in significant long-term growth, which investors hope will translate into gains in shareholder value.

  • Abeona Therapeutics, Inc. (ABEO) Stock Relatively Stable Following Positive Data for Sanfilippo Syndrome Treatment

    Abeona Therapeutics, Inc. (ABEO) stock prices were up 0.76% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.32 at the end of the trading day. Subsequent current market fluctuations saw the stock fall by 5.30%, bringing it down to USD$1.25.

    Promising Topline Data

    July 26th, 2021 saw ABEO stock announce magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A clinical study. The study indicated that ABO-102 increases grey matter, corpus callosum, and amygdala volumes in the brain. The study consisted of three young patients with Sanfilippo Syndrome Type A (MPS IIIA) at 24 months, compared to afflicted patients who did not receive treatment. The findings were presented by ABEO stock during an oral presentation at the 16th International Symposium on MPS and Related Diseases.

    Scope of Findings

    Brain volume loss is typical in children with MPS IIIA and is linked to long-term cognitive and physical disability. Grey matter has been found to be important for cognitive development, whereas the corpus callosum is crucial for motor function. The amygdala plays a critical role in fear learning as well as social/emotional development. The findings highlight the potential of ABO-102 to increase brain grey matter, corpus callosum, and amygdala volumes. This potential is in line with ABEO stocks’ previously reported results of preservation of neurocognitive development in the three young patients in the Transpher A study.

    ABEO Stock’s Study Endpoints

    The Transpher A study primary endpoints targeted neurodevelopment and the treatment’s safety. Secondary endpoints include, but are not limited to, brain volume, behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma, and urine, and liver volume.

    About the Study

    The Transpher A Study is a two-year process that is currently ongoing as an open-label, dose-escalation, Phase 1/2 global clinical trial. It is designed to assess the treatment of patients with Sanfilippo syndrome type A (MPS IIIA) with the use of ABEO stock’s ABO-102. The study is known as ABT-001 and is intended for patients ranging from birth to 2 years of age, or for patients older than 2 years with a cognitive developmental quotient of 60% or above.

    Future Outlook for ABEO

    Armed with the latest data from its highly promising study, ABEO stock is poised to capitalize on the opportunities ahead of it. The company is keen to push for the accelerated development and proliferation of ABO-102, which investors hope will translate into long-term gains in shareholder value.

  • GasLog Partners LP (GLOP) Stock Exhibits Volatility Following Disclosure of Q2 2021 Financial Reports

    GasLog Partners LP (GLOP) stock prices were up 4.78% as of the market close on July 26th, 2021, bringing the price per share up to USD$5.26 at the end of the trading day. Subsequent premarket fluctuations saw the stock fall by 11.60%, bringing it down to USD$4.65.

    GLOP Stock’s Charter Agreements

    GLOP stock recently announced three new time charter agreements with a string of companies: GasLog Sydney was chartered for one year in collaboration with a subsidiary of TotalEnergies SE; Solaris was chartered for eight months in a partnership with Royal Dutch Shell; and a deal with a wholly owned subsidiary of Cheniere Energy, which will see Methane Heather Sally being chartered for one to three years. The company also signed a new one-year time charter agreement with TotalEnergies for GasLog Seattle.

    Additional Recent Developments

    The second quarter of fiscal 2021 saw the company repay USD$18.8 million in debt, contributing to the USD$54.8 million of debt repaid over the first six months of 2021. GLOP stock also published the Partnership’s Sustainability Report for the previous year on July 20th, 2021. Effective August 1st, 2021, GLOP will see Mr. Eniozi, currently, Chief Operating Officer of GasLog, take over as director of the Partnership and as CEO of the Partnership.

    GLOP Stock Hits Quarter Milestone

    GLOP stock finalized previously scheduled dry-dockings for three vessels from its fleet: the Methae Rita Andrea, the GasLog Greece, and the GasLog Glasgow. This has resulted in a total of 82 scheduled off-hire days for the 2021 quarter, up from zero off-hire days reported for the second quarter of 2020.

    Financial Reports

    Revenue for the second quarter of 2021 was reported at USD$70.4 million, while profits for the quarter were reported at USD$14.7 million. Adjusted profit was USD$12.7 million for Q2 2021, with adjusted EBITDA reported at USD$45 million. Earnings per unit for the quarter came in at USD$0.14, with an adjusted earnings per unit of USD$0.10. the second quarter of fiscal 2021 also saw GLOP stock declare a cash distribution of USD$0.01 per common unit on record.

    Future Outlook for GLOP Stock

    Armed with a string of new strategic collaborations, GLOP stock is keen to continue its trajectory of success. The company is keen to continue expanding and consolidating its market footprint, with investors hopeful for organic growth and long term increases in shareholder value.

  • Powerbridge Technologies Co., Ltd. (PBTS) Stock on the Rise Following Announcement of SCM SaaS Platform

    Powerbridge Technologies Co., Ltd. (PBTS) stock prices were up 7.94% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.36 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 11.03%, bringing it up to USD$1.51.

    PBTS Stock’s Foray into Blockchain

    July 27th, 2021 saw the company reveal that it was in the process of building a Supply Chain Management SaaS platform that will be enabled by Blockchain technology. The company is keen to spearhead its foray into Blockchain technology in an effort to optimize and integrate traditional supply chain systems. PBTS stock is a cutting-edge tech company that focuses on providing artificial intelligence, the Internet of Things, Blockchain, and financial technologies.

    About the SaaS Platform

    The company also offers SaaS solutions and operational services in various fields such as cross-border trade, smart cities, and government services. PBTS stock’s Blockchain-enabled Supply Chain Management SaaS Platform is being designed to connect suppliers, logistics service providers, distributors, retailers, and end-users. It will do so with an integrative feature network, facilitating real-time information sharing for all participants. In doing so, the company ensures the credibility of the information and facilitates the efficiency of information transmission.

    Scope of Blockchain Technology

    PBTS stock hopes for its Blockchain management platform to prove to be applicable to more practical contexts, with a deep-rooted integration with businesses. The company intends to continue developing Blockchain applications and SaaS with more trials and innovations. The application of Blockchain technology is expected to generate sustained growth of PBTS’ revenue. PBTS will also expand its application to other fields, such as supply chain finance technology.

    About PBTS Stock

    With nearly 25 years of history behind it, PBTS stock aims to provide a myriad of smart-technology-based products and solutions. These offerings include global trade-related ports and customs management platforms, cross-border and global trade solutions, smart city tech products and solutions. The company also utilizes innovative technology such as Big Data, artificial intelligence, Blockchain, and the Internet of Things.

    Future Outlook for PBTS Stock

    Armed with its foray into the burgeoning blockchain market space, PBTS is poised to capitalize on its entry into a marketspace rife with opportunities. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • ObsEva SA (OBSV) Stock Skyrockets Following Global License Agreement with Organon

    ObsEva SA (OBSV) stock prices were up by 2.02% as of the market closing on July 26th, 2021, bringing the price per share up to USD$2.52 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 32.94%, bringing it up to USD$3.35.

    OBSV Stock Partners with Organon

    July 27th 2021 saw OBSV stock announce having entered into an agreement with Organon, wherein Organon will license the global development, manufacturing, and commercial rights to ebopriprant (OBE022). The treatment is an investigational, orally active, selective prostaglandin F2α receptor antagonist that is being evaluated as a potential treatment for preterm labor. It is designed to reduce inflammation and uterine contractions. Pending approval, the treatment has the potential to be a first-in-class innovation for a problem that is widespread and serious. Currently, there are no approved therapies for the acute treatment of preterm labor in the United States.

    Ebopriprant (OBE022)

    The asset is currently in the development-stage and is being studied to address a leading unmet need for women around the world. The agreement is set to consolidate the company’s path to sustained growth over the long term as it helps build Organon’s women’s health research and development portfolio. The partners share a vision to improve the women’s health landscape around the world, hoping to revolutionize the healthcare space.

    Facilitating Development

    Organon is an ideal strategic partner for OBSV stock in the collaborative drive to develop and commercialize ebopriprant. Collaboration is a critical step in advancing the investigational agent. While preterm births are on the rise, no other known compounds are currently in development. For this reason, the company is focused on evaluating the treatment of a significant area of unmet need.

    Details of Agreement

    As per the terms of the agreement, Organon is set to acquire exclusive global rights to develop and commercialize the treatment. OBSV stock will receive compensation via tiered double-digit royalties on commercial sales, as well as up to USD$500 million paid upfront and through milestone payments. Upon signing, OBSV is set to receive USD$25 million, up to USD$90 million in development and regulatory milestones, and up to USD$385 million sales based milestones.

    Future Outlook for OBSV

    Armed with its expansive new strategic partnership, OBSV stock is poised to capitalize on the additional opportunities within its reach. The company is keen to leverage the resources at its disposal to drive organic growth over the long term, thereby facilitating increases in shareholder value.